Keybanc maintains ICU Medical at Overweight, raises price target to $189 from $187

Keybanc maintained its Overweight rating on ICU Medical and increased its price target to $189 from $187, suggesting a 12.7% upside from the Nov 5 close of $167.65, according to the firm.

Original reporting
Published Nov 6, 2026, 2:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 2:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Keybanc maintains ICU Medical at Overweight, raises price target to $189 from $187 — source image
Decision brief

The 30-second read

$ICUNeutralLow
01

Why it matters

The upgrade may lead to incremental buying, but the magnitude is modest.

02

Market read

A small analyst rating change with limited immediate market impact.

03

What to watch

Potential upcoming earnings or product news could amplify the impact of the new target.

Relevance 5/10Novelty 3/10Timing: today

Background

Keybanc maintains an Overweight stance on ICU Medical and adjusts its price target upward.

Company-level read

Ticker impact

$ICUNeutralMedium confidence
Context

Keybanc raised ICU Medical's price target to $189 from $187, indicating a fresh analyst upgrade.

Expected impact

potential modest upside as investors price in the higher target

Evidence & confidence

The new target suggests a 12.7% upside from the recent close, but no immediate catalyst beyond the rating change.

Market effects

Minor positive signal for the medical device sector as a leading analyst upgrades a peer.

Limited to U.S. equities; no broader regional effect.

Low global relevance.

Counterpoint

Investors may view the modest target raise as insufficient to justify a position given limited upside.

Key entities

  • ICU Medical

    Medical device manufacturer listed on NYSE (ICU).

  • Keybanc

    Equity research analyst firm issuing the rating.

Related articles

$ICUHigh

SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates

SeaStar Medical Holding Corp (ICU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates Continued adoption of the QUELIMMUNE ® therapy yielded 247% increase in net revenue compared to the third quarter of 2025 Achieved nearly 75% enrollment in the NEUTRALIZE-AKI p